Eli Lilly has revealed plans to acquire Curevo for $1.5 billion, LimmaTech Biologics for $780 million, and Vaccine Company for $1.55 billion, totaling approximately $4 billion. This move aims to bolster its research and development efforts in infectious diseases, reflecting a proactive approach to disease prevention rather than merely treating existing conditions.
Following the announcement, Eli Lilly's shares increased by 1.3% in premarket trading, indicating positive investor sentiment towards the company's strategic direction. Daniel M. Skovronsky, the chief scientific and product officer, emphasized that these acquisitions are part of a deliberate strategy to address diseases at their source